Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Imatinib 400 mg Tablet
Therapeutic Category
Oncology, Anticancer
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
IMAFIX 400 Tablet (Imatinib 400 mg) is a highly specialized, oral, targeted cancer therapy classified as a Tyrosine Kinase Inhibitor (TKI). It is globally recognized as the revolutionary first-line treatment for Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML).
Imatinib works by selectively targeting and blocking the activity of the abnormal BCR-ABL fusion protein, a mutated tyrosine kinase that drives the uncontrolled proliferation of CML cells. By blocking this specific "switch," Imatinib effectively halts the progression of the disease, allowing many CML patients to achieve long-term molecular and cytogenetic remission.
Chronic Myeloid Leukemia (CML): The cornerstone therapy for newly diagnosed Ph+ CML in the chronic phase.
Gastrointestinal Stromal Tumors (GIST): Used to treat unresectable or metastatic GIST that expresses the c-Kit (CD117) positive receptor.
Acute Lymphoblastic Leukemia (ALL): Part of combination regimens for Ph+ ALL.
Due to the chronic nature of CML and the necessity for extended, often indefinite, patient dosing, Imatinib 400 mg maintains a remarkably stable and high-volume demand in the pharmaceutical market.
We offer an unparalleled PCD Pharma Franchise opportunity for IMAFIX 400. This specialization allows franchise partners to target institutional sales (oncology centers, large hospitals) and secure long-term revenue streams through a product of massive clinical importance and proven efficacy.
May cause nausea, vomiting, fatigue, low blood counts, hair loss, and bladder irritation. Rarely, neurotoxicity, kidney toxicity, or severe infections may occur.
Soft tissue and bone sarcomas Lymphomas Testicular cancer Other solid tumors as per oncologist’s guidance
Administer only under strict medical supervision in a hospital or oncology setting. Blood counts, liver, kidney, and bladder function should be regularly monitored. Adequate hydration and protective agents may be required to prevent bladder toxicity. Report any neurological symptoms, unusual bleeding, or infections promptly.
Store below 25°C, protected from light. Keep out of reach of children. Use immediately after reconstitution as per medical instructions.
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : Rosuvastatin 10mg + Clopidogrel 75mg Capsule
Composition : Rosuvastatin 20mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
Composition : Aspirin 75mg + Rosuvastatin 20mg + Clopidogrel 150mg Tablet
Composition : Rosuvastatin 20 mg + Ezetimibe 10 mg tablet
Composition : Rosuvastatin 10 mg tablet
Composition : Rosuvastatin (20mg) tablet
Composition : Rosuvastatin 10 mg + fenofibrate 160 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Imatinib 400mg Tablet is an anti-cancer targeted therapy (tyrosine kinase inhibitor) used in chronic myeloid leukemia (CML) and other malignancies, making it a highly specialized hospital and oncology prescription product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from steady institutional demand in oncology hospitals and cancer treatment centers. It is commonly prescribed by oncologists for long-term cancer management, ensuring consistent and high-value prescription cycles.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Imatinib 400mg Tablet with monopoly rights, oncology-grade manufacturing standards, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from stable hospital procurement, long-term cancer treatment cycles, and high-value specialty sales when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this oncology formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.